The Library
SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus : a systematic review and network meta-analysis
Tools
Shyangdan, Deepson S., Uthman, Olalekan A. and Waugh, Norman (2016) SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus : a systematic review and network meta-analysis. BMJ Open, 6 (2). e009417. ISSN 2044-6055.
PDF
WRAP_BMJ Open-2016-Shyangdan-.pdf - Published Version - Requires a PDF viewer. Available under License Creative Commons: Attribution-Noncommercial 4.0. Download (3907Kb) |
Abstract
Objective Because of the lack of head-to-head trials, the aim was to indirectly compare sodium glucose transporter-2 (SGLT-2) inhibitors in the treatment of type 2 diabetes.
Design Systematic review and network meta-analysis.
Data sources MEDLINE and EMBASE were searched from January 2005 to January 2015.
Eligibility criteria Randomised controlled trials assessing the efficacy of SGLT-2 inhibitors in patients with type 2 diabetes inadequately controlled with diet and exercise alone or metformin monotherapy. Minimum duration 24 weeks. Indirect comparison was undertaken using Bayesian methods.
Results In monotherapy, a greater proportion of patients achieved a glycated haemoglobin (HbA1c) level of <7% on canagliflozin 300 mg than on canagliflozin 100 mg (risk ratio (RR) 0.72%, 95% credible intervals (CrI) 0.59% to 0.87%) and dapagliflozin 10 mg (RR 0.63, 95% CrI 0.48 to 0.85) but there were no significant differences compared with either dose of empagliflozin. In monotherapy, canagliflozin 300 mg reduced HbA1c more than other SGLT-2 inhibitors (mean difference ranged from 0.20% to 0.64%). There were no significant differences in weight reduction. All the flozins reduced systolic blood pressure (SBP) more than placebo, ranging from a reduction of 6 mm Hg with canagliflozin 300–2.6 mm Hg with empagliflozin 10 mg. In dual therapy with metformin, all flozins were more effective than placebo for achieving HbA1c <7%, and reducing HbA1c, weight and SBP. The proportions achieving HbA1c level of <7% were mostly similar. Canagliflozin 300 mg reduced HbA1c more than the other drugs but this just reached statistical significance only against canagliflozin 100 mg (MD 0.15, CrI 0.04 to 0.26).
Conclusions There were few differences among the SGLT-2 inhibitors, but in monotherapy, the glucose-lowering effect of canagliflozin 300 mg is slightly greater than most other SGLT-2 inhibitors.
Item Type: | Journal Article | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Subjects: | R Medicine > RC Internal medicine | ||||||||||
Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School | ||||||||||
Library of Congress Subject Headings (LCSH): | Non-insulin-dependent diabetes -- Treatment | ||||||||||
Journal or Publication Title: | BMJ Open | ||||||||||
Publisher: | BMJ | ||||||||||
ISSN: | 2044-6055 | ||||||||||
Official Date: | 24 February 2016 | ||||||||||
Dates: |
|
||||||||||
Volume: | 6 | ||||||||||
Number: | 2 | ||||||||||
Article Number: | e009417 | ||||||||||
Status: | Peer Reviewed | ||||||||||
Publication Status: | Published | ||||||||||
Access rights to Published version: | Open Access (Creative Commons) | ||||||||||
Date of first compliant deposit: | 24 October 2016 | ||||||||||
Date of first compliant Open Access: | 24 October 2016 |
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |
Downloads
Downloads per month over past year